Transdermal Buprenorphine Dosing Interval Optimization from 7 Days to 5 Days: A Case Series

Area of Science:

• Pain Management
• Pharmacology
• Clinical Case Studies

Background:

• Transdermal buprenorphine is used for chronic pain management.
• Patients may experience end-of-dose failure, leading to insufficient pain relief.
• This necessitates exploring strategies to optimize transdermal buprenorphine efficacy.

Purpose of the Study:

• To evaluate the effectiveness of shortening the dosing interval of transdermal buprenorphine patches.
• To assess if a five-day interval improves pain control in patients with end-of-dose failure.
• To determine if this adjustment reduces reliance on rescue analgesics.

Main Methods:

• A case series design was employed.
• Three male patients with chronic pain were included.
• The dosing interval of transdermal buprenorphine patches was reduced from seven to five days based on reported end-of-dose failure.

Main Results:

• Patients reported enhanced pain control after switching to the five-day dosing interval.
• Improved functionality was observed in the patients.
• The adjustment appeared to mitigate the end-of-dose wearing-off effect.

Conclusions:

• Shortening the transdermal buprenorphine dosing interval to five days may be an effective strategy.
• This approach can potentially improve analgesic efficacy and patient safety.
• Reducing the dosing interval may decrease the need for supplementary pain medications.